These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 23774624)

  • 1. P-glycoprotein-dependent resistance of cancer cells toward the extrinsic TRAIL apoptosis signaling pathway.
    Galski H; Oved-Gelber T; Simanovsky M; Lazarovici P; Gottesman MM; Nagler A
    Biochem Pharmacol; 2013 Sep; 86(5):584-96. PubMed ID: 23774624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of the multidrug transporter P-glycoprotein is inversely related to that of apoptosis-associated endogenous TRAIL.
    Souza PS; Madigan JP; Gillet JP; Kapoor K; Ambudkar SV; Maia RC; Gottesman MM; Fung KL
    Exp Cell Res; 2015 Aug; 336(2):318-28. PubMed ID: 26101157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
    Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
    Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand.
    Mitsiades N; Poulaki V; Tseleni-Balafouta S; Koutras DA; Stamenkovic I
    Cancer Res; 2000 Aug; 60(15):4122-9. PubMed ID: 10945619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TRAIL sensitize MDR cells to MDR-related drugs by down-regulation of P-glycoprotein through inhibition of DNA-PKcs/Akt/GSK-3beta pathway and activation of caspases.
    Seo SB; Hur JG; Kim MJ; Lee JW; Kim HB; Bae JH; Kim DW; Kang CD; Kim SH
    Mol Cancer; 2010 Jul; 9():199. PubMed ID: 20663232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5.
    Park SJ; Wu CH; Choi MR; Najafi F; Emami A; Safa AR
    Biochem Pharmacol; 2006 Jul; 72(3):293-307. PubMed ID: 16753135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of TRAIL (Apo2L), DR4 (TRAIL receptor 1), DR5 (TRAIL receptor 2) and TRID (TRAIL receptor 3) genes in multidrug resistant human acute myeloid leukemia cell lines that overexpress MDR 1 (HL60/Tax) or MRP (HL60/AR).
    Kim CH; Gupta S
    Int J Oncol; 2000 Jun; 16(6):1137-9. PubMed ID: 10811986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TRAIL receptor signalling and modulation: Are we on the right TRAIL?
    Mahalingam D; Szegezdi E; Keane M; de Jong S; Samali A
    Cancer Treat Rev; 2009 May; 35(3):280-8. PubMed ID: 19117685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in established and primary glioma cell lines.
    Jaganathan J; Petit JH; Lazio BE; Singh SK; Chin LS
    Neurosurg Focus; 2002 Sep; 13(3):ecp1. PubMed ID: 15844877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
    Mitsiades N; Poulaki V; Mitsiades C; Tsokos M
    Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis.
    Evdokiou A; Bouralexis S; Atkins GJ; Chai F; Hay S; Clayer M; Findlay DM
    Int J Cancer; 2002 Jun; 99(4):491-504. PubMed ID: 11992538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human astrocytes are resistant to Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.
    Song JH; Bellail A; Tse MC; Yong VW; Hao C
    J Neurosci; 2006 Mar; 26(12):3299-308. PubMed ID: 16554480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of death receptor pathways in oncology.
    de Vries EG; Timmer T; Mulder NH; van Geelen CM; van der Graaf WT; Spierings DC; de Hooge MN; Gietema JA; de Jong S
    Drugs Today (Barc); 2003; 39 Suppl C():95-109. PubMed ID: 14988748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis.
    Jazirehi AR; Ng CP; Gan XH; Schiller G; Bonavida B
    Clin Cancer Res; 2001 Dec; 7(12):3874-83. PubMed ID: 11751478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rel/NF-kappaB transcription factors protect against tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by up-regulating the TRAIL decoy receptor DcR1.
    Bernard D; Quatannens B; Vandenbunder B; Abbadie C
    J Biol Chem; 2001 Jul; 276(29):27322-8. PubMed ID: 11350953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis.
    Locklin RM; Federici E; Espina B; Hulley PA; Russell RG; Edwards CM
    Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3219-28. PubMed ID: 18065493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitization of multidrug resistant human ostesarcoma cells to Apo2 Ligand/TRAIL-induced apoptosis by inhibition of the Akt/PKB kinase.
    Cenni V; Maraldi NM; Ruggeri A; Secchiero P; Del Coco R; De Pol A; Cocco L; Marmiroli S
    Int J Oncol; 2004 Dec; 25(6):1599-608. PubMed ID: 15547696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells.
    Pollack IF; Erff M; Ashkenazi A
    Clin Cancer Res; 2001 May; 7(5):1362-9. PubMed ID: 11350907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome-positive leukemia cells.
    Uno K; Inukai T; Kayagaki N; Goi K; Sato H; Nemoto A; Takahashi K; Kagami K; Yamaguchi N; Yagita H; Okumura K; Koyama-Okazaki T; Suzuki T; Sugita K; Nakazawa S
    Blood; 2003 May; 101(9):3658-67. PubMed ID: 12506034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transformation by oncogenic RAS sensitizes human colon cells to TRAIL-induced apoptosis by up-regulating death receptor 4 and death receptor 5 through a MEK-dependent pathway.
    Drosopoulos KG; Roberts ML; Cermak L; Sasazuki T; Shirasawa S; Andera L; Pintzas A
    J Biol Chem; 2005 Jun; 280(24):22856-67. PubMed ID: 15757891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.